What is NovoNutrients?
NovoNutrients is a pioneering biotechnology firm that specializes in the conversion of industrial carbon dioxide emissions into high-value proteins. By utilizing naturally occurring microbes and low-cost hydrogen, the company creates a sustainable alternative to traditional protein sources, specifically targeting the aquafeed sector. Based in Sunnyvale, California, the company operates at the intersection of industrial decarbonization and agricultural innovation. Its core technology platform is designed to transform waste streams into valuable commodities, effectively creating a circular economy model that reduces the environmental impact of industrial manufacturing while providing a scalable solution for global food security.
How much funding has NovoNutrients raised?
NovoNutrients has raised a total of $22.7M across 2 funding rounds:
Unspecified
$4.7M
Series A
$18M
Unspecified (2021): $4.7M with participation from Happiness Capital
Series A (2024): $18M led by Woodside Energy and CM Venture Capital
Key Investors in NovoNutrients
Woodside Energy
Woodside Energy is a major player in the Oil and Energy sector, focusing on large-scale energy production and strategic investments in sustainable industrial technologies.
CM Venture Capital
CM Venture Capital is a venture capital firm focused on investing in hard tech and science-backed technologies that drive innovation in energy systems and advanced materials.
Happiness Capital
Happiness Capital is an investment firm that supports early-stage ventures with a focus on long-term impact and sustainable innovation.
What's next for NovoNutrients?
With the successful closure of its Series A round, NovoNutrients is poised to scale its industrial pilot programs and refine its fermentation technology for broader market adoption. The strategic involvement of energy-sector partners suggests a focus on integrating carbon capture infrastructure directly into industrial sites, which could significantly lower production costs and improve the carbon footprint of the final protein product. Moving forward, the company will likely prioritize the optimization of its microbial strains and the establishment of commercial-scale production facilities. This phase of growth will be critical in validating the economic viability of its technology at scale, potentially setting a new standard for sustainable protein production in the global market.
See full NovoNutrients company page
